Anixa Biosciences Completes Breast Cancer Vaccine Trial, Awaits Full Results

Anixa's breast cancer vaccine trial is complete. Early results show it's well-tolerated and stimulates the immune system in most participants. Full results coming soon.

, and Administrator

2025 October 7 . 4:33 PM

1 min read

In this image we can see few people standing and a person is holding a vaccine bottle and there is... — In this image we can see few people standing and a person is holding a vaccine bottle and there is a calendar and text on the image.

Anixa Biosciences Completes Breast Cancer Vaccine Trial, Awaits Full Results

Anixa Biosciences has concluded patient visits for its breast cancer vaccine clinical trial. The study involved 35 women across three distinct groups: Triple-Negative Breast Cancer (TNBC), Prevention, and Pembrolizumab. Cleveland Clinic will present full results at the San Antonio Breast Cancer Symposium on December 11, 2025.

Preliminary findings indicate the vaccine is well-tolerated, with over 70% of participants showing protocol-defined immune responses. The vaccine is designed to stimulate the immune system to target breast cancer before it can recur or develop. Anixa believes its approach could represent a new paradigm in immuno-oncology for both prevention and treatment of breast cancer. Comprehensive data analysis can now proceed with the completion of all patient visits and sample collection. A final study report will be submitted to the Department of Defense, and a Clinical Study Report (CSR) will be filed with the FDA.

Anixa Biosciences, a clinical-stage biotechnology company focused on cancer treatment and prevention, has successfully completed its breast cancer vaccine trial. The company awaits the presentation of full clinical results by Cleveland Clinic at the San Antonio Breast Cancer Symposium in December 2025.